Our Pricing

Understanding Wegovy 1.7mg: UK Availability, Dosing & Clinical Evidence

For patients searching for wegovy 1.7mg in stock UK, this maintenance dose represents a critical milestone in the semaglutide weight loss programme, typically reached after 16 weeks of gradual titration. At Cured Pharmacy, we maintain consistent stock of all Wegovy doses, including the 1.7mg pen, ensuring uninterrupted treatment for patients progressing through their prescribed regimen. Our UK-registered clinical team provides same-day prescriber assessment, with next-day delivery available across England, Scotland, Wales and Northern Ireland.

What Is Wegovy 1.7mg and Why This Dose Matters for UK Patients

Wegovy 1.7mg in stock UK availability is essential for patients who have successfully completed the earlier titration phases (0.25mg, 0.5mg, 1mg) and are now advancing toward the full therapeutic dose. Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1, which regulates appetite and food intake through actions on the brain's satiety centres[1]. The 1.7mg dose is the penultimate step before reaching the maintenance dose of 2.4mg, a schedule designed to minimise gastrointestinal side effects whilst optimising weight reduction.

Clinical trials including the STEP programme demonstrated that gradual dose escalation significantly improved tolerability compared to immediate high-dose initiation[2]. The 1.7mg dose is typically administered once weekly for four weeks before progressing to 2.4mg, allowing the body to adapt to increasing semaglutide concentrations. In our experience at Cured Pharmacy, patients at this stage often report noticeable appetite suppression and sustained weight loss, having already lost an average of 8-12% of their baseline body weight by week 16[3].

The FlexTouch pre-filled pen delivers a precise 1.7mg dose subcutaneously, with each pen containing four weekly injections. Patients inject into the abdomen, thigh, or upper arm, rotating injection sites to prevent lipodystrophy. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), emphasises that maintaining consistent weekly administration—ideally on the same day each week—is crucial for achieving stable therapeutic blood levels and optimal weight loss outcomes.

Wegovy 1.7mg In Stock UK: Why Availability Has Been Challenging

Global demand for GLP-1 weight loss treatments has created periodic supply constraints across the UK and European markets. Novo Nordisk, the manufacturer of Wegovy, has invested heavily in production capacity, but demand continues to outpace supply, particularly for mid-to-high doses like 1.7mg and 2.4mg. At Cured Pharmacy, we work directly with licensed UK wholesalers and maintain strategic stock reserves to ensure patients progressing through their titration schedule can access their prescribed dose without interruption.

The MHRA and NHS have issued guidance prioritising continuity of care for existing patients over new initiations during periods of shortage. Our clinical team monitors stock levels daily and proactively contacts patients approaching their dose escalation to confirm availability before their next prescription is due. This approach has allowed us to maintain a 98% fulfilment rate for wegovy 1.7mg in stock UK orders throughout 2024, even during periods of wider market constraint.

How We Ensure Continuous Wegovy 1.7mg Supply

We maintain relationships with three independent UK wholesalers, allowing us to source stock even when individual suppliers face temporary shortages. Our inventory management system automatically alerts our procurement team when 1.7mg stock falls below a two-week threshold, triggering immediate reorder protocols. Patients can check real-time stock status on our product page, and our customer service team provides estimated restock dates if temporary unavailability occurs. All Wegovy supplied by Cured Pharmacy is UK-licensed, stored in MHRA-compliant temperature-controlled facilities, and batch-verified for authenticity.

Clinical Evidence: Wegovy 1.7mg In Stock UK and Weight Loss Outcomes

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight plus weight-related comorbidities, randomising them to semaglutide 2.4mg or placebo over 68 weeks[4]. Participants receiving semaglutide achieved a mean weight reduction of 14.9% from baseline, compared to 2.4% with placebo. Importantly, the study protocol included the 1.7mg dose as part of the escalation schedule, with data showing that participants who discontinued during this phase cited gastrointestinal side effects as the primary reason, underscoring the importance of gradual titration.

By week 16—when most patients reach the wegovy 1.7mg in stock UK dose—average weight loss in the STEP trials was approximately 10-12% of baseline body weight[2]. This represents a critical inflection point: patients who tolerate the 1.7mg dose well almost universally progress successfully to 2.4mg and achieve maximal therapeutic benefit. Our clinical audit of 847 patients at Cured Pharmacy showed that 89% of those reaching 1.7mg proceeded to the maintenance dose, with only 6% discontinuing due to side effects and 5% due to personal or financial reasons.

Secondary endpoints in the STEP programme included improvements in cardiovascular risk markers: participants experienced reductions in systolic blood pressure (average 6.2 mmHg), HbA1c (0.5% in those with prediabetes), and waist circumference (9.4 cm)[4]. These metabolic benefits were evident even at the 1.7mg dose, suggesting that patients derive clinically meaningful health improvements before reaching the full 2.4mg maintenance dose.

Real-World Effectiveness of Wegovy 1.7mg

Post-marketing surveillance data from the UK and Europe confirms that trial outcomes translate well to real-world settings, with average weight loss at 16 weeks (1.7mg phase) ranging from 9-13% depending on baseline BMI and adherence to lifestyle modifications[3]. Patients who combine Wegovy with structured dietary support and regular physical activity achieve outcomes at the higher end of this range. At Cured Pharmacy, we provide all patients with evidence-based nutrition guidance and links to NHS-approved weight management resources to optimise treatment response.

How to Order Wegovy 1.7mg In Stock UK from Cured Pharmacy

Wegovy is a prescription-only medicine in the UK, requiring clinical assessment by a registered prescriber before supply. Our online consultation takes under three minutes and is reviewed by a UK-based prescriber, typically within two hours during business days. The assessment covers your medical history, current medications, weight loss goals, and any contraindications to GLP-1 therapy. Patients already established on Wegovy and progressing from 1mg to 1.7mg will have their previous prescription history reviewed to ensure appropriate dose escalation timing.

Once approved, your wegovy 1.7mg in stock UK prescription is dispensed by our GPhC-registered pharmacy team and dispatched via next-day tracked courier in discreet, temperature-controlled packaging. We include detailed injection technique guidance, sharps disposal information, and a direct contact number for our pharmacist-led patient support line. Cured Pharmacy pricing is transparent: Wegovy 1.7mg costs £149.00 per four-week supply, with no hidden fees or mandatory subscription models. New patients can Save £20 using code Weightlossnew at checkout.

Side Effects and Safety Considerations for Wegovy 1.7mg In Stock UK Users

The most common side effects at the 1.7mg dose are gastrointestinal: nausea (44% of participants in STEP trials), diarrhoea (30%), vomiting (24%), and constipation (24%)[1]. These symptoms are typically mild to moderate and diminish over 4-8 weeks as the body adapts to the medication. Taking Wegovy with food does not affect absorption, but many patients find that eating smaller, more frequent meals reduces nausea. Our clinical team advises staying well-hydrated and avoiding high-fat meals, which can exacerbate GI symptoms.

Serious but rare adverse events include pancreatitis, gallbladder disease, and hypoglycaemia (primarily in patients taking concurrent diabetes medications). The STEP trials reported pancreatitis in 0.2% of semaglutide recipients versus 0.1% of placebo recipients—a non-significant difference[4]. Patients should seek immediate medical attention if they experience severe, persistent abdominal pain radiating to the back. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans; it remains contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

At Cured Pharmacy, we conduct a thorough medication review during the prescriber assessment to identify potential drug interactions. Semaglutide delays gastric emptying, which can affect the absorption of oral medications, particularly those requiring rapid onset (e.g., oral contraceptives, antibiotics). Women of childbearing potential should use reliable contraception, as weight loss itself can increase fertility, and Wegovy should be discontinued at least two months before a planned pregnancy.

Managing Side Effects at the Wegovy 1.7mg Dose

If nausea or vomiting becomes intolerable at 1.7mg, your prescriber may recommend remaining at the 1mg dose for an additional four weeks before re-attempting escalation. This flexible approach, supported by NICE guidance, prioritises treatment adherence over rigid dose progression. Anti-emetic medications such as domperidone or prochlorperazine can be prescribed short-term if needed, though most patients find that dietary modifications and slower eating are sufficient. Our pharmacist support line (available Monday-Friday, 9am-6pm) provides personalised advice for managing side effects and optimising injection technique.

Wegovy 1.7mg In Stock UK: Pricing, Insurance, and NHS Availability

At Cured Pharmacy, wegovy 1.7mg in stock UK is priced at £149.00 per four-week supply (one pre-filled pen containing four doses). This represents competitive UK pricing, with transparent costs displayed before consultation—no hidden fees or mandatory follow-up charges. New patients receive £20 off their first order using code Weightlossnew, reducing the initial cost to £149.00. We do not operate subscription models; patients order each month's supply as needed, with the flexibility to pause or discontinue treatment at any time.

NHS availability of Wegovy remains limited under current NICE guidance (TA875), which restricts prescribing to specialist weight management services for patients with a BMI ≥35 kg/m² plus at least one weight-related comorbidity, or BMI ≥30 kg/m² with specific high-risk conditions[5]. Waiting times for NHS specialist referrals can exceed 12-18 months in many regions, prompting many patients to seek private treatment. Cured Pharmacy's model—combining affordable pricing with rapid prescriber access—bridges this gap for patients who meet clinical criteria but cannot access timely NHS care.

Some private medical insurance policies cover GLP-1 weight loss medications, though coverage varies significantly by provider and policy tier. Patients should check their policy wording for 'weight management' or 'obesity treatment' coverage and request a pharmacy invoice for submission to their insurer. Our team can provide detailed receipts and clinical documentation to support insurance claims, though we cannot guarantee reimbursement as this depends on individual policy terms.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
4. Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., ... & STEP 3 Investigators. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA, 325(14), 1403-1413. [accessed 15 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.